Pacific Edge (NZE:PEB, ASX:PEB) said its product Cxbladder Triage has been included by the American Urological Association as the standard of care in an amendment to its clinical guideline for microhematuria patients, according to a Friday filing with the Australian and New Zealand bourses.
The guideline mentions the product as the only urine-based biomarker test that has "Grade A" evidence from a randomized controlled trial in support of this recommendation, the filing said.
Company shares rose 5% in recent Monday trade in New Zealand and jumped almost 22% in Australia.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。